Reviewing Evofem Biosciences Inc. (EVFM)’s and Rigel Pharmaceuticals Inc. (NASDAQ:RIGL)’s results

This is a contrast between Evofem Biosciences Inc. (NASDAQ:EVFM) and Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) based on their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Evofem Biosciences Inc. N/A 0.00 131.47M -7.47 0.00
Rigel Pharmaceuticals Inc. 6.65M 56.62 99.58M -0.65 0.00

Demonstrates Evofem Biosciences Inc. and Rigel Pharmaceuticals Inc. earnings per share, top-line revenue and valuation.


Table 2 provides us the return on equity, net margins and return on assets of both businesses.

Net Margins Return on Equity Return on Assets
Evofem Biosciences Inc. 0.00% 144.8% -836%
Rigel Pharmaceuticals Inc. -1,497.44% -97.7% -82.6%

Risk and Volatility

Evofem Biosciences Inc.’s volatility measures that it’s 179.00% more volatile than Standard and Poor’s 500 due to its 2.79 beta. From a competition point of view, Rigel Pharmaceuticals Inc. has a 1.29 beta which is 29.00% more volatile compared to Standard and Poor’s 500.


The Current Ratio of Evofem Biosciences Inc. is 0.5 while its Quick Ratio stands at 0.5. The Current Ratio of rival Rigel Pharmaceuticals Inc. is 6.1 and its Quick Ratio is has 6.1. Rigel Pharmaceuticals Inc. is better equipped to clear short and long-term obligations than Evofem Biosciences Inc.

Analyst Ratings

The next table highlights the given recommendations and ratings for Evofem Biosciences Inc. and Rigel Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Evofem Biosciences Inc. 0 0 0 0.00
Rigel Pharmaceuticals Inc. 0 0 1 3.00

On the other hand, Rigel Pharmaceuticals Inc.’s potential upside is 276.11% and its consensus price target is $8.5.

Insider & Institutional Ownership

Roughly 79.8% of Evofem Biosciences Inc. shares are owned by institutional investors while 96.5% of Rigel Pharmaceuticals Inc. are owned by institutional investors. Insiders owned roughly 3% of Evofem Biosciences Inc.’s shares. Competitively, 0.2% are Rigel Pharmaceuticals Inc.’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Evofem Biosciences Inc. 10% 8.15% -5.41% 2.67% -50.64% -67.09%
Rigel Pharmaceuticals Inc. -2.83% -12.42% -16.16% -14.6% -29.12% -29.12%

For the past year Evofem Biosciences Inc.’s stock price has bigger decline than Rigel Pharmaceuticals Inc.


Rigel Pharmaceuticals Inc. beats on 8 of the 10 factors Evofem Biosciences Inc.

Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women. The company is also developing vaginal gel product candidate for the treatment of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The companyÂ’s clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It is also developing two oncology product candidates, which are in Phase I and Phase II. Rigel Pharmaceuticals, Inc. has license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; Bristol-Myers Squibb Company for the discovery, development, and commercialization of cancer immunotherapies; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of an oncology program; and Daiichi Sankyo to pursue research related to ligases. The company was founded in 1996 and is based in South San Francisco, California.